

Quality control and quality assurance test in laboratories of API's

Pawar Vishakha Sandip¹, Shinde Divya Bhairvanath², Anbhule Sachin³

H.S.B.P.V.T.GOI faculty of pharmacy Kashti.

- **Abstract** : API's (Active Pharmaceutical Ingredients) are the active substance in pharmaceutical products that provide the therapeutic effect and these are core components of medication. For this API the quality control and quality assurance test performing is important. The fundamental principle of the given experiment is to ensure the efficacy and the efficiency of the experimental API's. In this experiment researcher can gain the knowledge about the technological equipment used to perform the process. In that the various equipment can be used.

- **Keywords** : API's , Quality Control test , Quality Assurance, Laboratory Equipment
- **Introduction** :

Objectives :

1. To assess the current state of QC/QA practices in pharmaceuticals companies/labs, identifying strength , opportunities.
2. To identify the best practices in QC/QA , including innovative technologies, methods, and strategies.
3. Ensuring patient safety, efficacy and the products quality.

➤ ***Quality Control And Quality Assurance :***

❖ ***Quality Control*** : It is a process that helps a company make sure it creates quality products and that staff and management alike make minimal mistakes.

❖ ***Quality Assurance*** : Quality assurance in the pharmaceutical industry is a set of process+ that the safety, efficacy, and purity of medications. Primary goal of QA is to prevent issues and ensure that the final product meets predetermined specifications. QA also aims to build and maintain customer confidence in the product.


➤ ***Key aspects of QA –***

- Quality assurance plan
- Good Manufacturing Practices
- Adverse event investigation
- Corrective and preventive actions plans.

➤ ***API's*** : Active pharmaceutical ingredient is the substance in a drug that produces the desired medical effect. API's can be Synthetic or Natural.


Quality Control	Quality Assurance
Reactive	Proactive
Narrow process	Broad process
Goals is to detect mistakes or errors in a product	Goal is to prevent quality failures
Takes place after development	Takes place through the development process
Line function	Staff function

❖ **Quality Control Flow chart :**




❖ **Quality Assurance Flow Chart :**

Quality Assurance Process



❖ Stages Of Pharmaceutical manufacturing :



❖ **Active Pharmaceutical Ingredients :**

- The **API** is the central ingredient. APIs are produced from raw materials with a specified strength and chemical concentration.

How Do APIs Work?

APIs work by interacting with cells within your body to produce their intended effects. For example, painkillers like ibuprofen and aspirin contain APIs that interact with your body's cells to reduce inflammation and relieve pain. Other types of drugs may contain APIs that interact with different parts of your body to produce different results – antibiotics may kill bacteria while antidepressants may help regulate moods by affecting brain chemicals like serotonin and dopamine levels

➤ **In the quality control test there are various equipments are used :**

1. Ph meter
2. Hardness tester
3. Dissolution apparatus
4. Disintegration apparatus
5. Spectrophotometer
6. Friability tester
7. HPLC

8. TLC
9. Incubator
10. Autoclave, etc.

1) ***pH meter :***



A pH meter is a scientific instrument used to measure the acidity or alkalinity (pH) of a solution.

ranges of pH is from 0-14

- pH 0-1 being strongly acidic (e.g., hydrochloric acid)
- pH 7 being neutral (e.g., pure water)
- pH 13-14 being strongly alkaline (e.g., sodium hydroxide)

➤ **Procedure :** 1. Prepare pH meter

2. Calibration

3. Measurement (prepare sample ,take reading)

4. Post – Measurement (clean electrode , maintain meter)

2) ***Dissolution Apparatus :***



A dissolution apparatus, also known as a dissolution tester, is a laboratory device used to measure the dissolution rate of pharmaceutical dosage forms, such as tablets, capsules, and injectables.

➤ **Procedure :**

1. Prepare sample and dissolution medium.

2. Set apparatus parameters (temperature, agitation rate, sampling times).

3. Add sample to vessel.

4. Start test.

5. Collect and analyze samples.

➤ **Application :**

1. Pharmaceutical development: Formulation optimization and quality control.

2. Bioequivalence studies: Comparing generic drugs to innovator products.
3. Quality control: Ensuring product consistency and stability.

3) Disintegration apparatus :



A disintegration tester is a laboratory device used to evaluate the disintegration time of pharmaceutical dosage forms, such as tablets, capsules, and suppositories.


➤ Procedure :

1. Prepare sample (tablet, capsule, or suppository)
2. Fill disintegration tube with water (or specified medium)
3. Add sample to tube
4. Place tube in tester
5. Set temperature ($37^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$) and timing device
6. Observe and record disintegration time

➤ Application : 1. Tablets (immediate/controlled release)

2. Capsules (hard/soft gelatin)
3. Suppositories
4. Buccal tablets
5. Sublingual tablets

4) Spectrophotometer :



A spectrophotometer is an analytical instrument used to measure the interaction between light and matter, detecting and quantifying the absorption, transmission, or reflection of light by molecules.

➤ Principle

1. Light passes through the sample.
2. Molecules absorb specific wavelengths.

3. Detector measures transmitted or reflected light.

4. Absorbance (A) or transmittance (T) calculated.

❖ **Applications:**

1. Pharmaceutical analysis (drug concentration, purity)


2. Biotechnology (protein quantification, DNA/RNA analysis)

3. Environmental monitoring (water, soil, air quality)

4. Food and beverage analysis (nutrient content, contamination)

5. Clinical diagnostics (blood analysis, medical research)

❖ **Methodology :**



References :

1. Busemann Sokole E, et al. Routine quality control recommendations for nuclear medicine instrumentation. *Eur J Nucl Med Mol Imaging*. 2010;37(3):662–71.
2. Stout DB, et al. Small animal imaging center design: the facility at the UCLA Crump Institute for Molecular Imaging. *Mol Imaging Biol*. 2005;7(6):393–402.
3. Kuntner C, Stout D. Quantitative preclinical PET imaging: opportunities and challenges. *Front Phys*. 2014;2: 12.
4. ES, et al. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. *PLoS Biol*. 2010;8(3): e1000344.
5. van der Worp HB, et al. Can animal models of disease reliably inform human studies? *PLoS Med*. 2010;7(3): e1000245.
6. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? *Nat Rev Drug Discov*. 2011;10(9):712.
7. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. *Nature*. 2012;483(7391):531–3.
8. Boellaard R. Standards for PET image acquisition and quantitative data analysis. *J Nucl Med*. 2009;50(Suppl 1):11S-20S.
9. Boellaard R, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *Eur J Nucl Med Mol Imaging*. 2015;42(2):328–54.
10. Boellaard R, et al. EARL procedure for assessing PET/CT system specific patient FDG activity preparations for quantitative FDG PET/CT studies. *Eur J Nucl Med Mol Imaging*. 2014;42:328–54.
11. <https://doi.org/10.1007/s11306-022-01926-3>
12. <https://doi.org/10.1007/s11306-022-01926-3>

- 13 <https://doi.org/10.1007/s11306-022-01926-3>
- 14 Bijlsma, S., Bobeldijk, I., Verheij, E.R., Ramaker, R., Kochhar, S., Macdonald, I.A., Van Ommen, B. & Smilde, A.K. (2006). Large-scale human metabolomics studies: A strategy for data (pre-) processing and validation. *Analytical Chemistry*, 78(2), 567–574.
- 15 Broadhurst, D., Goodacre, R., Reinke, S.N., Kuligowski, J., Wilson, I.D., Lewis, M.R., & Dunn, W.B. (2018). Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. *Metabolomics*, 14(6), 1–17.
- 16 Committee for Medicinal Products for Human Use. (2011). Guideline on bioanalytical method validation. *European Medicines Agency*
- 17 Dudzik, D., Barbas-Bernardos, C., García, A., & Barbas, C. (2018). Quality assurance procedures for mass spectrometry untargeted metabolomics a review. *Journal of Pharmaceutical and Biomedical Analysis*, 147, 149–173.
- 18 17. Evans, A. M., O'Donovan, C., Playdon, M., Beecher, C., Beger, R.D., Bowden, J.A., Broadhurst, D., Clish, C.B., Dasari, S., & Dunn, W.B. (2020). Dissemination and analysis of the quality assurance (QA) and quality control (QC) practices of LC–MS based untargeted metabolomics practitioners. *Metabolomics*, 16(10), 1–16.